ACQUISITIONS, DIVESTITURES, LICENSING AND OTHER ARRANGEMENTS - Narrative (Details) $ / shares in Units, $ in Millions	1 Months Ended			6 Months Ended	12 Months Ended				36 Months Ended
	Jan. 31, 2024 USD ($) right $ / shares	Nov. 30, 2023 USD ($)	Oct. 31, 2023 USD ($)	Jun. 30, 2024 USD ($) $ / shares	Dec. 31, 2023 USD ($)	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)	Dec. 31, 2014	Dec. 31, 2026
Business Acquisition [Line Items]
Royalty Income					$ 862	$ 832	$ 666
Keytruda Royalties
Business Acquisition [Line Items]
Percentage of net sales payable to alliance partner					6.50%
Keytruda Royalties | Forecast | Subsequent Event
Business Acquisition [Line Items]
Percentage of net sales payable to alliance partner									2.50%
LianBio Co. Ltd. | Mavacamten Rights
Business Acquisition [Line Items]
Payments for asset acquisitions			$ 445
Payments to acquire rights			$ 350
Bristol-Myers Squibb | Keytruda Royalties | Forecast | Subsequent Event
Business Acquisition [Line Items]
Payment and royalty allocation									75.00%
Ono | Keytruda Royalties | Forecast | Subsequent Event
Business Acquisition [Line Items]
Payment and royalty allocation									25.00%
Immatics
Business Acquisition [Line Items]
License and other arrangements upfront payments						150
Contingent and regulatory milestone payments						770
Agenus
Business Acquisition [Line Items]
License and other arrangements upfront payments							200
Contingent and regulatory milestone payments							1,400
Dragonfly
Business Acquisition [Line Items]
License and other arrangements upfront payments						175
Mavacamten
Business Acquisition [Line Items]
Payment to extinguish future royalty obligation						295
Diabetes business - royalties
Business Acquisition [Line Items]
Royalty Income					$ 862	810	622
Diabetes business - royalties | Supply Agreements
Business Acquisition [Line Items]
Royalty Income					960	924	725
Diabetes business - royalties | Amelyn, Onglyza, and Farxiga
Business Acquisition [Line Items]
Business sale royalty expense					98	114	103
Mature products and other
Business Acquisition [Line Items]
Royalty Income					$ 0	22	$ 44
Mature products and other | Discontinued Operations, Held-for-sale
Business Acquisition [Line Items]
Liabilities held for sale						20
Assets held for sale						172
Mature products and other | Cost of products sold
Business Acquisition [Line Items]
Asset impairment charges						63
Mature products and other | LOTTE Corporation
Business Acquisition [Line Items]
Sales price						159
Minimum | Diabetes business - royalties
Business Acquisition [Line Items]
Percentage of net sales payable to alliance partner								10.00%
Maximum | Diabetes business - royalties
Business Acquisition [Line Items]
Percentage of net sales payable to alliance partner								25.00%
Orum
Business Acquisition [Line Items]
Payments for asset acquisitions		$ 100
Asset acquisition, consideration transferred, contingent consideration		$ 80
Mirati Therapeutics | Subsequent Event
Business Acquisition [Line Items]
Business acquisition, share price (in usd per share) | $ / shares	$ 58.00
Payments to acquire businesses, gross	$ 4,800
Acquisition, net of cash acquired	$ 4,100
Business combination, contingent value, number of rights received | right	1
Business combination, contingent value payout, period	7 years
Mirati Therapeutics | Forecast
Business Acquisition [Line Items]
Business combination, contingent value, share price (in dollars per share) | $ / shares	$ 12.00
Contingent consideration liability	$ 1,000
Karuna | Forecast
Business Acquisition [Line Items]
Payments to acquire businesses, gross				$ 14,000
Acquisition, share price (in dollars per share) | $ / shares				$ 330.00
RayzeBio | Forecast
Business Acquisition [Line Items]
Payments to acquire businesses, gross				$ 4,100
Acquisition, share price (in dollars per share) | $ / shares				$ 62.50
Turning Point
Business Acquisition [Line Items]
Payments to acquire businesses, gross						4,113
Acquisition, net of cash acquired						$ 3,300